secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2025-04-22T23:59:59+00:00
Accession:  0000950170-25-056724
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences appoints medtech veteran Gary Burbach to board of directors
--------------------------------------------------------------------------

- Appointed as Class II director effective April 21, 2025; term expires at 2026 annual meeting.
- Former CEO of Thoratec (acquired by St. Jude/Abbott); also serves on BWX Technologies and Procyrion boards.
- CEO Paul Badawi highlighted Burbach's commercial and operational expertise in medtech.
- Eligible for non-employee director compensation; no committee assignments yet determined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025056724/0000950170-25-056724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025056724/sght-20250421.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-056724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer